Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies

BACKGROUND: Mirikizumab, an anti-IL-23p19 antibody, demonstrated efficacy in phase 3, randomized, double-blind, placebo-controlled LUCENT-1 (induction/NCT03518086) and LUCENT-2 (maintenance/NCT03524092) ulcerative colitis (UC) studies. We evaluated the effect of mirikizumab on quality-of-life (QoL)...

Descripción completa

Detalles Bibliográficos
Autores principales: Sands, Bruce E, Feagan, Brian G, Hunter Gibble, Theresa, Traxler, Kristina A, Morris, Nathan, Eastman, William J, Schreiber, Stefan, Jairath, Vipul, Long, Millie D, Armuzzi, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684049/
https://www.ncbi.nlm.nih.gov/pubmed/38034882
http://dx.doi.org/10.1093/crocol/otad070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684049/
https://www.ncbi.nlm.nih.gov/pubmed/38034882
http://dx.doi.org/10.1093/crocol/otad070

Ejemplares similares